Q3 FY26 — 20 Jan 2026
SRF Q3 FY26
SRF delivered a robust Q3 FY26, with significant growth in EBIT and PAT, primarily driven by strong performance in the Chemicals Business, especially Fluorochemicals. Despite facing headwinds like persistent Chinese pricing pressure in Specialty Chemicals and demand deferment in agrochemicals, the company maintained momentum through operational excellence and strategic investments. SRF is confident about future opportunities, supported by a strong pipeline and ongoing capacity expansion for new generation gases and pharma intermediates.
Read the full call






